Stifel Upgrades Tandem Diabetes Care to Buy, Announces $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman upgraded Tandem Diabetes Care (TNDM) from Hold to Buy and set a price target of $37.
March 26, 2024 | 8:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel upgraded Tandem Diabetes Care to Buy from Hold and set a price target of $37.
Upgrades by analysts, especially from Hold to Buy, typically signal a positive outlook on the stock, suggesting potential upside. The new price target of $37 by Stifel indicates a significant expected increase in TNDM's stock price, which could attract investor interest and drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100